zolmitriptan 2.5mg tablets
waymade healthcare plc - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 5mg tablets
waymade healthcare plc - zolmitriptan - oral tablet - 5mg
zolmitriptan 2.5mg tablets
de pharmaceuticals - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 2.5mg tablets
sandoz ltd - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 2.5mg tablets
lupin healthcare (uk) ltd - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 2.5mg tablets
mawdsley-brooks & company ltd - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 2.5mg tablets
kent pharma (uk) ltd - zolmitriptan - oral tablet - 2.5mg
zolmitriptan 5mg tablets
a a h pharmaceuticals ltd - zolmitriptan - oral tablet - 5mg
zolmitriptan 2.5mg tablets
crescent pharma ltd - zolmitriptan - oral tablet - 2.5mg
zolmitriptan tablet, film coated
ingenus pharmaceuticals, llc - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan tabletsare indicated for the acute treatment of migraine with or without aura in adults. limitations of use - only use zolmitriptan tablets if a clear diagnosis of migraine has been established. if a patient has no response to zolmitriptan tablets treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan tablets are administered to treat any subsequent attacks. - zolmitriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of zolmitriptan tablets have not been established for cluster headache. zolmitriptan is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c oronary artery vasospasm including prinzmetal’s angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway